Read the latest press releases from Calliditas Therapeutics by clicking on a title below.

For press enquiries please contact us.

Interim Report Q2, 2019

Strategic in-licensing related to autoimmune hepatitis in the US market

Calliditas Therapeutics to host conference call to provide Business Update and 2019 Q2 report

Number of shares and votes in Calliditas Therapeutics

Calliditas has resolved on a directed share issue in the amount of 3.5 million shares, raising proceeds of approximately SEK 210 million

Calliditas considers a directed share issue

Calliditas Therapeutics and Everest Medicines Enter into an Agreement to Develop and Commercialize Nefecon for IgA Nephropathy in Greater China and Singapore

Calliditas Therapeutics to Present at Redeye Growth Day

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

Interim Report Q1, 2019

Calliditas Therapeutics to host conference call to provide Business Update and 2019 Q1 report

Elmar Schnee and Diane Parks proposed as new board members of Calliditas Therapeutics

Notice of annual general meeting of Calliditas Therapeutics AB (publ)

Calliditas Therapeutics’ 2018 Annual Report published

Calliditas Therapeutics to Present at the Needham Healthcare Conference

Calliditas Therapeutics to Present at March Investor Conferences

Calliditas Therapeutics granted orphan drug designation by the FDA for Primary biliary cholangitis

Year-end report, 2018

Calliditas Therapeutics granted orphan drug designation by the FDA for Autoimmune hepatitis

Calliditas Therapeutics to host conference call to provide Business Update and 2018 full-year report

Calliditas Therapeutics appoints Frank Bringstrup as VP Regulatory Affairs

Calliditas Therapeutics appoints Andrew Udell to VP Commercial, North America